1. Home
  2. COUR vs EWTX Comparison

COUR vs EWTX Comparison

Compare COUR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COUR
  • EWTX
  • Stock Information
  • Founded
  • COUR 2012
  • EWTX 2017
  • Country
  • COUR United States
  • EWTX United States
  • Employees
  • COUR N/A
  • EWTX N/A
  • Industry
  • COUR Computer Software: Prepackaged Software
  • EWTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • COUR Technology
  • EWTX Health Care
  • Exchange
  • COUR Nasdaq
  • EWTX Nasdaq
  • Market Cap
  • COUR 1.1B
  • EWTX 1.2B
  • IPO Year
  • COUR 2021
  • EWTX 2021
  • Fundamental
  • Price
  • COUR $7.31
  • EWTX $13.45
  • Analyst Decision
  • COUR Buy
  • EWTX Buy
  • Analyst Count
  • COUR 14
  • EWTX 8
  • Target Price
  • COUR $10.34
  • EWTX $40.38
  • AVG Volume (30 Days)
  • COUR 1.8M
  • EWTX 3.0M
  • Earning Date
  • COUR 04-24-2025
  • EWTX 05-08-2025
  • Dividend Yield
  • COUR N/A
  • EWTX N/A
  • EPS Growth
  • COUR N/A
  • EWTX N/A
  • EPS
  • COUR N/A
  • EWTX N/A
  • Revenue
  • COUR $694,674,000.00
  • EWTX N/A
  • Revenue This Year
  • COUR $5.78
  • EWTX N/A
  • Revenue Next Year
  • COUR $5.21
  • EWTX N/A
  • P/E Ratio
  • COUR N/A
  • EWTX N/A
  • Revenue Growth
  • COUR 9.27
  • EWTX N/A
  • 52 Week Low
  • COUR $5.76
  • EWTX $10.60
  • 52 Week High
  • COUR $12.37
  • EWTX $38.12
  • Technical
  • Relative Strength Index (RSI)
  • COUR 57.21
  • EWTX 32.10
  • Support Level
  • COUR $5.76
  • EWTX $10.77
  • Resistance Level
  • COUR $7.03
  • EWTX $13.60
  • Average True Range (ATR)
  • COUR 0.34
  • EWTX 1.66
  • MACD
  • COUR 0.11
  • EWTX 0.03
  • Stochastic Oscillator
  • COUR 98.73
  • EWTX 22.76

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: